More Articles

Access and Evidence

Thinking Outside The Box

Adam Chapman, (Sep 5, 2017)

In digital, it’s all about personalization. Isn’t it time pharma caught up with other industries?
Access and Evidence

Finding Common Ground: Australian Government Seeks Closer Ties With Pharma

Adam Chapman, (Aug 30, 2017)

The Australian government asks for pharma’s help to ensure patients gain fast access to new medicines

Patient-Centricity: Decoding The Buzzword

Adam Chapman, (Aug 24, 2017)

No matter how you slice it, pharma companies across the industry are scrambling to be perceived as putting the patient first. But who is making good on this? What more needs to be done?
Access and Evidence

Big Data, Huge Opportunity

Nancy Bergquist, (Aug 22, 2017)

Insights derived from big data are transforming the healthcare landscape, offering marketers a high-definition view of the patient and customer

An Unexpected Journey

Des Sampson, (Aug 21, 2017)

A better understanding of the patient journey is increasingly informing company strategy

Patient Engagement: A Slow Dance?

Lucy Fulford, (Aug 2, 2017)

Patients and pharma need to overcome their awkwardness if they are to work together for the betterment of all, says patient advocate Jasmine Wright
Access and Evidence

When Real-World Evidence met Patient-Centricity

Hugh Gosling, (Jul 28, 2017)

If real-world evidence and patient-centricity teamed up could they cure all of pharma’s ills?

Only One Thing Can Save Pharma

Katie Osborne, (Jul 25, 2017)

Innovation is essential for pharma's future success, but where does it come from and how do you build it into an organization?

From Push To Pull: The Reinvention Of Marketing

Hugh Gosling, (Jul 20, 2017)

As customers turn away from traditional ‘push’ marketing channels, companies are using insights into their behavior to pull customers in, but performing the U-turn from push to pull has not been easy.

The Human Side of Patient-Centricity

Lucy Fulford, (Jul 12, 2017)

Focus on patient need and business success should follow, says Paul Perreault, CEO of leading biotechnology firm CSL Limited, parent company of CSL Behring